Low-dose tiagabine effectiveness in anxiety disorders

MedGenMed Medscape General Medicine

Volumn 6, Issue 3, 2004, Pages

  Schaller, James L ^a   Thomas, John ^b,c   Rawlings, David ^d,e  

^a Professional Medical Services of Naples   (United States)

^b Life Counseling Services   (United States)

^c Horsham Clinic   (United States)

^d Neuropsychology Consultants   (United States)

^e Naples Community Hospital Healthcare System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CARBAMAZEPINE; CLONAZEPAM; GABAPENTIN; LAMOTRIGINE; METHYLPHENIDATE; OXCARBAZEPINE; PAROXETINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIAGABINE; TOPIRAMATE; VIGABATRIN;

ADOLESCENT; ADULT; ANIMAL CELL; ANORGASMIA; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DOSE RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; INSOMNIA; LOW DRUG DOSE; MALE; MYALGIA; NAUSEA; NONHUMAN; RAT; RATING SCALE; RESTLESSNESS; SUBSTANCE ABUSE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 25144514487     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Tiihonen J, Kuikka J, Rasanen P, et al. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis. Mol Psychiatry. 1997;2:463-471.
2. Smith TA. Type A gamma-aminobutyric acid (GABAA) receptor subunits and benzodiazepine binding: significance to clinical syndromes and their treatment. Br J Biomed Sci. 2001;58:111-121.
3. Goddard AW, Mason GF, Almai A, et al. Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Arch Gen Psychiatry. 2001;58:556-561.
4. Bremner JD, Innis RB, White T, et al. SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry. 2000;47:96-106.
5. Davis LL, Ryan W, Adinoff B, et al. Comprehensive review of the psychiatric uses of valproate. J Clin Psychopharmacol. 2000;20:1S-17S.
6. Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol. 2000;20:467-471.
7. Uhlenhuth EH, Balter MB, Ban TA, et al. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997. Depress Anxiety. 1999;9:107-116.
8. Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry. 2003;64:1245-1249.
9. Berigan T. Treatment of posttraumatic stress disorder with tiagabine. Can J Psychiatry. 2002;47:788.
10. Zwanzger P, Baghai TC, Schule C, et al. Tiagabine improves panic and agoraphobia in panic disorder patients. J Clin Psychiatry. 2001;62:656-657.
11. Crane D. Tiagabine for treatment of anxiety. Depress Anxiety. 2003;18:51-52.
12. Schwartz TL. The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series. Psychopharmacol Bull. 2002;36:53-57.
13. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893-897.
14. Ward MF, Wender PH, Reimherr FW. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150:885-890.
15. Pavone A, Cardile V. An in vitro study of new antiepileptic drugs and astrocytes. Epilepsia. 2003;44:S34-S39.
16. Sills GJ. Pre-clinical studies with the GABAergic compounds vigabatrin and tiagabine. Epileptic Disord. 2003;5:51-56.
17. Cardile V, Palumbo M, Renis M, Pavone A, Maci T, Perciavalle V. Tiagabine treatment and DNA damage in rat astrocytes: an in vitro study by comet assay. Neurosci Lett. 2001;306:17-20.